An Innovative Policy in the Law of Innovation: So Why the Outcry?
Tuesday, November 13th, 2007In January 2006, the Patent Office of Chennai rejected the patent application by Novartis for patent of the drug Gleevec (chemically known as imatinib mesylate). Since then till date, the Novartis saga has prompted numerous headlines and scores of commentaries. What is so unique about the entire controversy? After all, aren’t patent applications rejected by ...